Indications and uses
Helps prevent sunburn.
LBEL CLARITE Clarifying Effect Foundation SPF 30
- Manufacturer
- Ventura International LTD | Bel Star S.A. (Colombia)
- Effective date
- 2019-12-23
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 3
- Source
- legacy-cache
- Hydrated at
- 2026-08-01 23:49:22
Label at a glance#
ProductLBEL CLARITE Clarifying Effect Foundation SPF 30 CLAIRE 1- BEIGE
Active ingredientOctinoxate, Oxybenzone, Zinc Oxide
Label structure18 sections
Dosage and administration
Apply liberally and evenly 15 minutes before sun exposure. Reapply at least every 2 hours Use a water resistant sunscreen if swimming or sweating. Children under 6 months of age: Ask a doctor
Storage and handling
Protect the product in this container from excessive heat and direct sun.
Label contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
Drug Facts
OTC - ACTIVE INGREDIENT SECTION
OTC - PURPOSE SECTION
| Active Ingredients | Purpose |
|---|---|
| OCTINOXATE 7.50 % | Sunscreen |
| OXYBENZONE 2.00 % | Sunscreen |
| ZINC OXIDE 1.96 % | Sunscreen |
Uses
- Helps prevent sunburn.
Warnings
SPL UNCLASSIFIED SECTION
- Skin Cancer / Skin Aging Alert: Spending time in the sun increases your risk of skin cancer and early skin aging. This product has been shown only to help prevent sunburn, not skin cancer or early skin aging.
- For external use only.
OTC - DO NOT USE SECTION
- Do not use on damaged or broken skin.
OTC - WHEN USING SECTION
- When using this product keep out of eyes. Rinse with water to remove.
OTC - STOP USE SECTION
- Stop use and ask a doctor if rash occurs.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
- Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
Directions
- Apply liberally and evenly 15 minutes before sun exposure.
- Reapply at least every 2 hours
- Use a water resistant sunscreen if swimming or sweating.
- Children under 6 months of age: Ask a doctor
Other information
- Protect the product in this container from excessive heat and direct sun.
Inactive ingredients
ISOSTEARYL NEOPENTANOATE, MICA, C12-15 ALKYL BENZOATE, ETHYLHEXYL PALMITATE, POLYMETHYL METHACRYLATE, DIMETHICONE/VINYL DIMETHICONE CROSSPOLYMER, OZOKERITE, KAOLIN, COPERNICIA CERIFERA CERA (COPERNICIA CERIFERA (CARNAUBA) WAX), ZEA MAYS STARCH (ZEA MAYS (CORN) STARCH), KOJIC DIPALMITATE, DIMETHICONE, OCTYLDODECANOL, PHENOXYETHANOL, GLYCERYL ISOSTEARATE, ISOSTEARYL ALCOHOL, SILICA, BUTYROSPERMUM PARKII BUTTER (BUTYROSPERMUM PARKII (SHEA) BUTTER), CERA MICROCRISTALLINA (MICROCRYSTALLINE WAX), CAPRYLYL GLYCOL, BETA-SITOSTEROL, CHLORPHENESIN, PARFUM (FRAGRANCE), CANDELILLA CERA (EUPHORBIA CERIFERA (CANDELILLA) WAX), TRIMETHYLSILOXYSILICATE, GLYCYRRHIZA GLABRA ROOT EXTRACT (GLYCYRRHIZA GLABRA (LICORICE) ROOT EXTRACT), PETROLATUM, PHOSPHOLIPIDS, TRIETHOXYCAPRYLYLSILANE, CHOLESTEROL, CETEARYL ALCOHOL, CETEARYL GLUCOSIDE, POLYGLYCERYL-2 DIPOLYHYDROXYSTEARATE, SYNTHETIC BEESWAX, GLYCOSPHINGOLIPIDS, POLYETHYLENE.
MAY CONTAIN : CI 77891 (TITANIUM DIOXIDE), CI 77492 (IRON OXIDES), CI 77491 (IRON OXIDES), CI 77499 (IRON OXIDES).
SPL UNCLASSIFIED SECTION
Dist. by Ventura Int Ltd. DBA Belcorp USA, Miami, FL 33126
PRINCIPAL DISPLAY PANEL - 9 g Case Box - CLAIRE 1 - BEIGE
L'BEL
CLARITÉ
Clarifying effect foundation SPF 30
Net Wt. 0.31 oz. e (9 g)
PRINCIPAL DISPLAY PANEL - 9 g Case Box - CLAIRE 2 - BEIGE
L'BEL
CLARITÉ
Clarifying effect foundation SPF 30
Net Wt. 0.31 oz. e (9 g)
PRINCIPAL DISPLAY PANEL - 9 g Case Box - CLAIRE 3 - BEIGE
L'BEL
CLARITÉ
Clarifying effect foundation SPF 30
Net Wt. 0.31 oz. e (9 g)
PRINCIPAL DISPLAY PANEL - 9 g Case Box - CLAIRE 4 - BEIGE
L'BEL
CLARITÉ
Clarifying effect foundation SPF 30
Net Wt. 0.31 oz. e (9 g)
PRINCIPAL DISPLAY PANEL - 9 g Case Box - MEDIUM 5 - BEIGE
L'BEL
CLARITÉ
Clarifying effect foundation SPF 30
Net Wt. 0.31 oz. e (9 g)
PRINCIPAL DISPLAY PANEL - 9 g Case Box - MEDIUM 6 - BEIGE
L'BEL
CLARITÉ
Clarifying effect foundation SPF 30
Net Wt. 0.31 oz. e (9 g)
PRINCIPAL DISPLAY PANEL - 9 g Case Box - MEDIUM 7 - BEIGE
L'BEL
CLARITÉ
Clarifying effect foundation SPF 30
Net Wt. 0.31 oz. e (9 g)
PRINCIPAL DISPLAY PANEL - 9 g Case Box - OBSCURE 8 - BROWN
L'BEL
CLARITÉ
Clarifying effect foundation SPF 30
Net Wt. 0.31 oz. e (9 g)
PRINCIPAL DISPLAY PANEL - 9 g Case Box - OBSCURE 9 - BROWN
L'BEL
CLARITÉ
Clarifying effect foundation SPF 30
Net Wt. 0.31 oz. e (9 g)
PRINCIPAL DISPLAY PANEL - Kit Label
L'BEL
CLARITÉ
Clarifying effect foundation SPF 30
Net Wt. 0.31 oz. e (9 g)
FDA-Initiated Inactive NDC Indexing#
Products#
Every source-derived product name is available through these pages.
- LBEL CLARITE Clarifying Effect Foundation SPF 30 CLAIRE 1- BEIGE
- Octinoxate, Oxybenzone, and Zinc Oxide
- Octinoxate
- Oxybenzone
- Zinc Oxide
- ISOSTEARYL NEOPENTANOATE
- MICA
- ALKYL (C12-15) BENZOATE
- ETHYLHEXYL PALMITATE
- POLY(METHYL METHACRYLATE; 450000 MW)
- CERESIN
- KAOLIN
- CARNAUBA WAX
- STARCH, CORN
- KOJIC DIPALMITATE
- DIMETHICONE
- OCTYLDODECANOL
- PHENOXYETHANOL
- GLYCERYL ISOSTEARATE
- ISOSTEARYL ALCOHOL
- SILICON DIOXIDE
- SHEA BUTTER
- MICROCRYSTALLINE WAX
- CAPRYLYL GLYCOL
- .BETA.-SITOSTEROL
- CHLORPHENESIN
- CANDELILLA WAX
- GLYCYRRHIZA GLABRA
- PETROLATUM
- LECITHIN, SOYBEAN
- TRIETHOXYCAPRYLYLSILANE
- CHOLESTEROL
- CETOSTEARYL ALCOHOL
- CETEARYL GLUCOSIDE
- POLYGLYCERYL-2 DIPOLYHYDROXYSTEARATE
- HIGH DENSITY POLYETHYLENE
- TITANIUM DIOXIDE
- FERRIC OXIDE YELLOW
- FERRIC OXIDE RED
- FERROSOFERRIC OXIDE
NDC Codes#
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| dfa191da-bde8-4f15-b3db-1569f752ffa1 | ef59cff1-2d75-40f7-838d-dfd1a62bf8b7 | 2019-12-23 | Warnings | dfa191da-bde8-4f15-b3db-1569f752ffa1 ef59cff1-2d75-40f7-838d-dfd1a62bf8b7 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.